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Ceftazidime-avibactam has potent sterilizing activity
against highly drug-resistant tuberculosis
Devyani Deshpande,1 Shashikant Srivastava,1 Moti Chapagain,1 Gesham Magombedze,1
Katherine R. Martin,1 Kayle N. Cirrincione,1 Pooi S. Lee,1 Thearith Koeuth,1
Keertan Dheda,2 Tawanda Gumbo1,2*
There are currently many patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Ongoing transmission of the highly drug-resistant strains and high mortality despite treatment remain prob-
lematic. The current strategy of drug discovery and development takes up to a decade to bring a new drug to
clinical use. We embarked on a strategy to screen all antibiotics in current use and examined them for use in
tuberculosis. We found that ceftazidime-avibactam, which is already used in the clinic for multidrug-resistant
Gram-negative bacillary infections, markedly killed rapidly growing, intracellular, and semidormant Mycobacterium
tuberculosis in the hollow fiber system model. Moreover, multidrug-resistant and extensively drug-resistant clinical
isolates demonstrated good ceftazidime-avibactam susceptibility profiles and were inhibited by clinically achievable
concentrations. Resistance arose because of mutations in the transpeptidase domain of the penicillin-binding
protein PonA1, suggesting that the drug kills M. tuberculosis bacilli via interference with cell wall remodeling.
We identified concentrations (exposure targets) for optimal effect in tuberculosis, which we used with susceptibility
results in computer-aided clinical trial simulations to identify doses for immediate clinical use as salvage therapy for
adults and young children. Moreover, this work provides a roadmap for efficient and timely evaluation of antibiotics
and optimization of clinically relevant dosing regimens.
INTRODUCTION
Highly drug-resistant tuberculosis (TB) has left a large number of patients
therapeutically destitute and functionally incurable (1, 2). In South Africa,
we found that 60% of such difficult-to-treat patients have unfavorable out-
comes and are dead within 10 months of discharge (3). These highly drug-
resistant cases spread the infection before death, and 50% of the secondary
cases were dead by the end of the study. Newer antibiotics such as bedaqui-
lineanddelamanid improveoutcomesbutdonoteliminate treatment failure.
In patients with extensively drug-resistant TB receiving bedaquiline, the
24-month treatment failure rate was 38%, and patients with isolates re-
sistant to both bedaquiline and delamanid are being documented with
increasing frequency (4–6). The field urgently needs new treatments
that can be deployed immediately without waiting for drug and clinical
development programs that can take almost a decade.
One solution is reuse of antibiotics and other therapieswith proven
clinical safety records that are already known to penetrate lung lesions. We
disregarded the standard dogma that only certain special antibiotic classes
would be effective against Mycobacterium tuberculosis (Mtb) and created a
programtodeliberately examineall antibacterial agents incurrent clinicaluse.
We screened several antibiotic compounds in test tubes and then
quickly moved to identify optimal doses for possible clinical use on the
basis of the hollow fiber system model of TB (HFS-TB) (7). The HFS-TB
allows for quick examination of drug efficacy based on human lung phar-
macokinetics and for immediate translationof results fromthe laboratory to
the clinic. TheHFS-TB has a 94% predictive accuracy for clinical therapeu-
tic events, such as dose, concentrations/exposures optimal in patients, and
expected rates of clinical efficacy, and has been formally qualified as a drug
development toolby theEuropeanMedicinesAgency (EMA)andendorsed
by the U.S. Food andDrug Administration (FDA) for this purpose (8–10).
Recent chemical screens have shown several older cephalosporins, in
combinationwith the b-lactamase inhibitor clavulanate, as potential anti-
TB agents (11). However, there are several drawbacks. First, clavulanate
inhibition ofMtb’s broad-spectrum b-lactamase, BlaC, is slow and rela-
tively inefficient. Second, clavulanate is currently only available for imme-
diate use in combination with amoxicillin and not with cephalosporins.
Third, amoxicillin-clavulanate administered for several months for TB is
likely to be associated with high rates of side effects, such as diarrhea.We
screened several other cephalosporins for anti-TB effect when in combi-
nation with the non–b-lactam b-lactamase inhibitor avibactam, which
potently inhibits BlaC. One of these, ceftazidime, was first marketed
almost 40 years ago and has no activity againstMtb and other Gram-
positive bacteria (12). It was recently coformulated with avibactam, and
this combination is already in clinical use for Gram-negative bacterial in-
fections.Ceftazidime-avibactam(CAV)hasa serumto lungepithelial lining
fluid penetration of 32%, which makes it a good drug for pneumonias
(13). We tested for CAV efficacy in the HFS-TB using clinically achieva-
ble intrapulmonary pharmacokinetics.We examined threeMtbmetabol-
ic subpopulations encountered in cavitary TB: logarithmic phase growth
bacteria (log-phase growth) that are ordinarily killed by isoniazid in what
is defined as bactericidal activity, intracellular Mtb, and semidormant
bacteria under acidic conditions that are ordinarily killed by the combi-
nation of pyrazinamide and rifampin as part of the sterilizing effect
(14–17). Other more potent cephalosporin-avibactam combinations
were identified. However, we focused on CAV because this coformu-
lation is available for immediate use as salvage therapy.
RESULTS
Program for rapid discovery and translation for antibiotic
reuse to treat drug-resistant TB
Our screening, discovery, and translation programhas several steps out-
lined in Fig. 1. In step 1, we screened for CAV activity against log-phase
growth and intracellularMtb and then identified theminimum inhibitory
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concentration (MIC) distribution in multidrug-resistant (MDR) and ex-
tensively drug-resistant (XDR) TB clinical isolates. In step 2, we used the
CAV concentration-time profiles encountered in patients to identify the
bactericidal and sterilizing effect rates in theHFS-TB. In step 3, theHFS-TB
resultswereused togetherwith theknownbetween-patientpharmacokinetic
variability of CAV to translate results to TB programs and for clinical trials.
These steps allowed for delivery of a dosing regimen for clinical use in less
than 9months,making the drug immediately available for clinical studies.
Screening to identify effect of CAV against Mtb
The efficacy of first-line drugs in the HFS-TB, as well as in the clinic,
is well known, which makes them ideal benchmarks. Figure 1 shows
that our first step was to perform concentration-effect studies of the
first-line drugs along with CAV against log-phase growth Mtb in
Middlebrook 7H9broth (hereinafter “broth”) in test tubes and inphorbol
myristate ester–activated human-derived THP-1 monocytes infected
with Mtb in 24-well plates, using Mtb H37Ra, as described previously
Fig. 1. Program for rapid screening and translation for reuse of antibiotics in TB. In the first step of the program, we examined the effect of CAV in comparison to
standard first-line agents in intracellular and extracellular assays in a biosafety level 2 (BSL2) laboratory using avirulent Mtb. After demonstrating potential effectiveness, we then
identified the MIC distribution in X/MDR-TB clinical strains from South Africa, in a BSL3 laboratory. In this first step, static concentrations of CAV were used. In step 2, we examined
the efficacy of intrapulmonary concentration-time profiles of the CAV in the HFS-TB in several strains, for both bactericidal and sterilizing effect. These studies with dynamic
concentrations of CAV against different Mtb metabolic subpopulations identified the concentrations and exposures associated with optimal kill and resistance suppression. They
also generated CAV-resistant isolates, which then underwent whole-genome sequencing (WGS) to explore for mechanisms of effect. Step 3 takes place in silico, and uses output of
step 2 as well as population-level pharmacokinetic parameters and measures of between-patient pharmacokinetic variability, plus MIC distributions from step 1, in Monte Carlo
experiments to identify optimal clinical doses for use in patients with drug-resistant TB and for susceptibility breakpoints for decision-making of whom should be treated with the
drug. Step 4 involves handing over of the clinical dose for immediate clinical trial studies and salvage therapy.
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(18–20). We used commercially available CAV (ceftazidime/avibactam
ratio of 4:1), whichwas purchased fromour hospital pharmacy.Maximal
Mtb kill, denoted by the symbol Emax, was 0 to 1.43 log10 colony-forming
units (CFU)/ml for pyrazinamide and 3.32 to 3.56 log10 CFU/ml for iso-
niazid, whereas that for rifampin was 5.30 to 5.68 log10 CFU/ml, after
7 days of coincubation (Fig. 2,A toC).Neither ceftazidimenor avibactam
alone killedMtb, even a little (Fig. 2, D and E). However, the combined
CAV killed Mtb with an Emax of 4.19 to 7.05 log10 CFU/ml, exceeding
isoniazid andpyrazinamide and equaling rifampin, at concentrations that
are clinically achievable (Fig. 2, F and G). A repeat study of ceftazidime
concentration combined with avibactam at a concentration of either 0,
1, 5, or 15 mg/liter revealed that a minimum avibactam concentration
of 1mg/literwas needed to confer the ceftazidimemicrobial kill. Because
neither ceftazidime alone nor avibactam alone killedMtb, but CAV did
(Fig. 2, F and G), the reason for the poor activity of ceftazidime against
Mtb is not the lack of a penicillin-binding protein target but b-lactamase
activity.
Drug-resistant Mtb clinical isolates are susceptible to CAV
Next, we determined how widespread the CAV susceptibility is among
Mtb isolates, using twoMIC assays. Five laboratory isolates had identical
MICs in microbroth dilution and Mycobacteria Growth Indicator Tube
BACTEC (MGIT) assays, at MICs shown in Fig. 2H. Next, we used the
MGIT assay to identify MICs for 25 clinical strains from South Africa,
which included 80% X/MDR-TB strains representing all known Mtb
phylogenetic lineages. We identified the MIC distribution shown in
Fig. 2H. This shows that the MICs of 24 of the 25 (96%) clinical strains
were below theCAVpeak concentrations of 90 to 100mg/liter, achieved
with therapeutically achievable concentrations at standard doses. Thus,
most clinical strains fromX/MDR-TBpatientswere susceptible toCAV.
CAV human-like intrapulmonary pharmacokinetics have
high bactericidal effects
The HFS-TB allows us to perform dose-response studies using
concentration-time profiles of antibiotics at the site of infection.We used
the HFS-TB of log-phaseMtbH37Ra to recapitulate the intrapulmonary
concentration-timeprofiles of sevenCAVdoses using the same commer-
cially available CAV formulation (ceftazidime/avibactam ratio of 4:1)
administered every 8 hours for 27 days; each infusion was administered
over 2 hours, on the basis of pharmacokinetics reported to the FDA and
EMA for licensing purposes, and had a half-life of 3.3 hours (13, 14, 21).
We measured the CAV concentrations in each HFS-TB, and pharmaco-
kineticmodeling confirmed the half-life of 3.3 hours. Figure 3A shows that
CAV achievedmarkedmicrobial kill of the log-phase growthMtb at bac-
tericidal effect kill rates higher than standarddose isoniazid, pyrazinamide,
and rifampin monotherapy with drug-susceptibleMtb in the HFS-TB in
the past (18, 22, 23). Figure 3A shows an unprecedented effect in theHFS-
TB,which is 6.0 log10CFU/mlkill in just 7days; themost effective first-line
drugs of isoniazid and rifampin have a kill of <2.0 log10 CFU/ml over the
same time period in the same HFS-TB model and in sputum of patients
(15, 22, 23). Thus, at a minimum, CAV administered with human-like
pharmacokinetics demonstrated a bactericidal effect exceeding that of
first-line drugs as monotherapy and in combination.
CAV therapeutic exposure targets are time-dependent
Next, we wanted to identify the dosing schedule and optimal concentra-
tions or exposures (defined as concentration/MIC) that are associated
with maximal microbial kill and resistance suppression. We used a
dose-fractionation design and a slightly faster half-life, which allowed
us to examine the effects of different dosing schedules and exposure
patterns by breaking colinearity that would accompany dose changes,
as shown in the drug concentration–time profiles we measured in each
HFS-TB in Fig. 3 (B toD).We achieved a half-life of 2.6 ± 0.3 hours (r2 =
0.99). Figure 3 (B to D) shows that the percentage of time (24 hours) that
CAV concentration persisted above MIC (%TMIC) was lowest with the
once-a-day dosing schedule, followed by twice a day, although the peak
concentrations were the same despite dosing schedule. Thus, we achieved
the experimental design objective. The effect onMtb burdenwas assessed
using two methods: determining CFU per milliliter (CFU/ml), which is
commonly used in the research laboratory, and determining time to pos-
itivity (TTP) in the MGIT, which is more commonly used by clinicians
and correlates with long-term treatment outcomes (24, 25). On the basis
of the Akaike information criteria scores for exposure versus bacterial
burden model fits, the %TMIC was the best driver of microbial kill by
both CFU/ml and TTP, better than peak-to-MIC and area under the
concentration-time curve to MIC (AUC/MIC). This means that the
CAV effect againstMtbwill be optimized by the three-times-a-day dos-
ing schedule, and the once-a-day dosing schedule would kill less. Figure 3E
and fig. S1 show these exposure-effect relationships between %TMIC and
Mtb burden for each sampling day. We used these exposure-effect re-
lationships to calculate the CAV exposure that would achieve the same
kill rates in the HFS-TB and in the sputum of patients as those of the
first-line drugs, which are 1.95 log10 CFU/ml (or 0.28 log10 CFU/ml per
day) for rifampin, 1.8 log10 CFU/ml (or 0.6 log10 CFU/ml per day) for
isoniazid during the first 7 days, and 0.10 log10 CFU/ml per day after the
first 4 days for pyrazinamide (15, 18, 22, 23, 26, 27). The CAV exposure
that achieved the same kill rates as those of the most active of the first-
line drugs was a %TMIC of≥47%.We also calculated the CAV exposure
associated with maximal kill, which was a %TMIC of ≥63%. Therefore,
CAVhas to be dosed at exposures exceeding a%TMIC of 63% (that is, 63
to 100%) for optimal efficacy. Exposure target values are known to be
the same between the HFS-TB and TB patients (8, 27, 28). Thus, the %
TMIC values of 47 and 63% are the exposure targets thatmust be achieved
or exceeded by CAV doses in patients to achieve the same amounts of
microbial kill in patients, as was observed in the HFS-TB (8, 27, 28).
We alsomodeled the size of the drug-resistant subpopulation (CFU/
ml), capturedusingCAVconcentrationof six timesMIConagar (18, 28).
The size of the drug-resistant subpopulation was driven by the AUC/
MIC ratio achieved, as shown in Fig. 3F, with suppression of acquired
drug resistance at an AUC/MIC ratio of 250. We collected 12 of the
CAV-resistant isolates, confirmed that they grew at a CAV concentra-
tion of 96 mg/liter in broth, and then extracted DNA for WGS. We
identified 149 single-nucleotide variants (SNVs) common to the 12
CAV-resistant isolates not present in the wild type, shown in table
S1. The nonsynonymous SNVs are shown in Fig. 4. Excluding the mu-
tations in the highly polymorphic genes encoding proteins carrying
proline–glutamic acid (PE) or proline–proline–glutamic acid (PPE)
motif, there were a total of 53 genes with at least one SNV, mostly in
genes encoding cell wall and membrane components and processes.
The most notable SNVs included genes encoding the bifunctional
penicillin-binding protein ponA1 (average coverage of 192 times)
transpeptidase domain, rpfE (average coverage of 200 times) encod-
ing Mtb’s lytic transglycosylase, and secretion system genes. In sev-
eral resistant isolates (but not all), there was also a mutation in rpfA,
which encodes the lytic transglycosylase. Notably, there were nomu-
tations in blaC, LdtMt1, and LdtMt2 (average coverage of 125 times).
We confirmed the lack of mutations in blaC, LdtMt1, and LdtMt2 in a
second DNA extraction of the strains using Sanger sequencing.
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A B
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Fig. 2. Exposure effect screening study of CAV against Mtb. Each concentration was examined in triplicate, and results shown are for mean and SD (error bar). For
each study, concentration versus log10 CFU/ml was examined using the inhibitory sigmoid Emax model. (A) Pyrazinamide failed to kill intracellular Mtb in 7 days. We
acidified broth, which enabled pyrazinamide to kill Mtb but had poor fit of the model to the data (r2 = 0.718), associated with maximal kill (Emax) of 1.43 ± 1.07 log10
CFU/ml. (B) Isoniazid Emax was 3.56 ± 0.10 log10 CFU/ml against intracellular Mtb (r
2 = 0.988), similar to the Emax of 3.32 ± 0.33 log10 CFU/ml (r
2 = 0.845) for extracellular
Mtb. (C) Rifampin Emax for intracellularMtb was 5.68 ± 0.30 log10 CFU/ml (r
2 = 0.976), and that for extracellular bacteria was 5.30 ± 0.09 log10 CFU/ml (r
2 = 0.996). (D) Ceftazidime
alone did not killMtb. (E) There was also poor fit of the model to the data for avibactam because of minimal to no microbial kill by the avibactam (r2 = 0.357). (F) CAV achieved
an Emax of 7.05 ± 0.00 log10 CFU/ml and an EC50 (median effective concentration) of 104.50 ± 13.44 mg/liter (r
2 = 0.910) against extracellular Mtb. This EC50 is easily achieved
with standard doses. (G) CAV achieved an Emax of 4.19 ± 0.29 log10 CFU/ml and an EC50 of 74.92 ± 9.03 mg/liter (r
2 = 0.960) against intracellular Mtb. (H) CAV MICs for five
laboratory isolates are shown by arrows. The modal MIC in clinical isolates was 32 mg/liter.
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Both ceftazidime and avibactam are highly concentrated
inside Mtb-infected cells
To determine whether CAV would be effective against intracellularMtb,
we infected THP-1 monocytes with Mtb, as described above, and then
inoculated them into HFS-TB conditioned with RPMI and 2% fetal bo-
vine serum(FBS) (19, 20).HFS-TB replicateswere then treatedwithCAV
daily for 26 days, which we confirmed by repetitive sampling of both the
central compartment (systemic concentrations) andMtb-infectedmono-
cytes. Figure 5A shows the concentrations of ceftazidime and avibactam
achieved inside the Mtb-infected monocytes: The concentrations
achieved by both drugs at all time points were much higher inside the
monocytes than extracellularly. Thus, all CAV-treated systems achieved
Fig. 3. Bactericidal effect of CAV in the HFS-TB. Data for each unit in replicate HFS-TB are shown separately. (A) In the first HFS-TB study, CAV was administered three
times per day to each HFS-TB system, to produce concentration-time profiles similar to the stated human doses. The lowest human equivalent dose of 0.75 g demonstrated
significant kill below the day 0 bacterial burden (stasis) of 2.78 log10 CFU/ml. At a dose of 6 g, the day 0 burden of 6.2 log10 CFU/ml was reduced to 0, indicating marked speed
of bactericidal effect that is greater than isoniazid’s 1.8 log10 CFU/ml in the HFS-TB and in patients, which is the most effective first-line drug against log-phase growth
Mtb. (B to D) In the second HFS-TB study, triplicate HFS-TBs were treated with CAV in a dose-fractionation design. Concentration-time profiles achieved with once-a-day
dosing schedule (B) had the lowest proportion of time above MIC (%TMIC), compared to the twice-a-day dosing schedule (C) that had matching peak concentrations; %
TMIC was highest with the dosing schedule of every 8 hours (D). (E) The inhibitory sigmoid Emax model for CFU/ml versus %TMIC had an r
2 of 0.94 on day 8. (F) The
relationship between AUC/MIC and CAV-resistant CFU/ml had an r2 of 0.90; the ratio associated with resistance suppression can be read off the graph as a ratio of 250.
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a %TMIC of 100% both extracellularly and intracellularly. Microbial kill
results based onTTP are shown in Fig. 5B, showing that the CAVmono-
therapy increased TTP >2-fold from day 0. Figure 5C shows thatMtb in
untreated controlHFS-TB replicates grew at an average rate of 0.119 log10
CFU/ml [95% confidence interval (CI), 0.051 to 0.186], with maximal
growth rate of 0.293 log10 CFU/ml (95% CI, 0.156 to 0.429) in the first
10 days. Figure 5C further demonstrates that in theCAV-treatedHFS-TB
replicates, microbial kill was 3.0 log10 CFU/ml below that of day 0, and
with a difference of >5 log10 CFU/ml with untreated controls. This kill
rate magnitude is in the same range as that of the three first-line drugs
combined in the sameHFS-TBmodel in thepast (29). These resultsmean
that CAVkills the intracellularMtb subpopulation and has the advantage
of high intracellular penetration.
CAV sterilizing effect is similar to that of the three first-line
drugs in combination
Next, we wanted to compare the sterilizing effect of CAVmonotherapy
to the first-line drug combination (isoniazid, rifampin, and pyrazin-
amide). We used the HFS-TB model of extracellular semidormant
MtbH37Rv, in broth acidified to pH 5.8 (18), treated three times daily
for 6 weeks. The drug concentrations we measured and the exposures
achieved in each replicate HFS-TB are shown in Fig. 6A. Because a
%TMIC of 100% and the exposures of first-line drugs achieved are those
associated with optimal microbial kill for each, we compared the best
possible sterilizing effect of CAV to the best of the first-line drug combina-
tion. Figure 6B shows that untreated controls grew very slowly in thisHFS-
TBmodel, at a rate of 0.026 log10CFU/ml (95%CI, 0.009 to 0.04), which
0 kb
200 kb
400 kb
600 kb
800 kb
1000 kb
34
00
 k
b
36
00
 k
b
38
00
 kb
400
0 k
b
4200
 kb
12
00
 k
b
14
00
 
kb
16
00
 kb
180
0 k
b
2000 
kb
2200 kb
2400
 kb
2600 kb
2800 kb
3000
 kb
3200 kb
R
v0
01
2
R
v0
05
0
R
v0
06
4
R
v0
08
2
R
v0
10
1
R
v0
10
9
R
v0
19
7
R
v0
20
4c
R
v0
27
8c
R
v0
27
9c
R
v0
32
3c
R
v0
35
5c
Rv
03
88
c
Rv
04
42
c
Rv
04
73
Rv
05
32
Rv
065
8c
Rv0
746
Rv08
33
Rv0890
c
Rv0930
Rv0966c
Rv1021
Rv1180
Rv1253Rv1266c
Rv1394cRv1452c
R
v1783
R
v1815
R
v1925
R
v1979c
R
v2037c
R
v2048c
R
v2101
R
v2
34
6c
R
v2
35
0c
R
v2
35
1cR
v2
45
0cRv
24
95
c
Rv
262
7c
Rv2
702
Rv2
741
Rv2896
c
Rv2930
Rv2933
Rv2961
Rv3011c
Rv3021c
Rv3144c
Rv3331
Rv3479
Rv3508
Rv3511
Rv3514
Rv3565
R
v3620c
R
v3879c
R
v3919c
Fig. 4. Mutations in theMtb genome of resistant mutants. Shown are the mutations that were common to all 12 drug-resistant isolates. Cell wall and cell membrane
component genes are in magenta, including those for Rv0012 (PonA1).
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is 11.27 times slower than the intracellular population and is in the
expected range for semidormant bacilli (30). There was a biphasic de-
cline inCFU/mlwithCAVmonotherapy treatment, a 2.3 log10 CFU/ml
decline during the first week, followed by a slower decline, which was
nevertheless sustained for up to 6 weeks. The microbial kill by the stan-
dard three-drug combination therapy, although better than that of the
CAV monotherapy, was only marginally so. By the end of the experi-
ment on day 42, the CAV monotherapy had killed exactly the same as
the first-line drug combination. Thus, CAV monotherapy may have a
sterilizing effect that is only slightly less than that of the three-drug first-
line drug combination.
Treatment of X/MDR-TB and incurable TB would be achieved
with doses tolerated by patients
The main drivers of therapeutic outcomes in TB patients are pharma-
cokinetic variability and Mtb isolate MICs (31–37). The translational
pathway that starts withHFS-TB findings, followed byMonte Carlo sim-
ulations that take into account the pharmacokinetic and MIC varia-
bility, has a quantitative forecasting accuracy of 94% for identified
optimal doses and susceptibility breakpoints (8, 28). Exposure target
A
B
C
Fig. 5. Pharmacokinetics and efficacy of CAV in intracellular Mtb. Mean values
and SDs (error bars) are shown in three replicates each. Given the range of concen-
trations, we used a log10 scale for drug concentrations and intracellular to extra-
cellular ratios for pharmacokinetic parameters and concentrations. (A) There were
much higher concentrations achieved for both avibactam and ceftazidime inside
the infected monocytes compared to those outside. (B) TTP increased 2.2-fold (max-
imal) on CAV alone, consistent with decreased bacterial burden. (C) Mtb CFU/ml re-
veals ~3.0 log10 CFU/ml decline below day 0 burden with CAV treatment.
A
B
Fig. 6. Sterilizing effect of CAV versus standard combination therapy. We
compared the sterilizing effect of CAV to standard first-line drug combination in three
replicates of hollow fiber systems for each treatment condition. Standard therapy
consists of rifampin, isoniazid, and pyrazinamide, with ethambutol added in the
beginning in case there is isoniazid resistance, and is dropped when susceptibility
results become available; with some new point of care diagnostics, isoniazid suscep-
tibility is actually known quickly, and ethambutol was excluded. In the figures, the
mean value is shown with SD error bars. On many sampling days, the error bars were
too small (SD was very low) and are obscured by the symbol. (A) First-line drug ex-
posures achieved in the replicate HFS-TB. The MICs were 0.125 mg/liter for rifampin,
0.06 mg/liter for isoniazid, and 12.5 mg/liter for pyrazinamide, in Mtb H7Rv. (B) The
mean Mtb burden progressively declined throughout the course of treatment with
CAV to a kill of 4.72 log10 CFU/ml below stasis (day 0 bacterial burden) at the end of
the study on day 42. It can also be seen that starting on day 35, the CAV effect was
similar to the standard three-drug regimen.
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values are known to be the same between the HFS-TB and TB patients;
thus, the same exposure targets of a%TMIC of either 47 or 63%were used
to translate CAV efficacy from the laboratory to the clinic (8, 27, 28).
To identify the CAV clinical dose that would achieve or exceed the
exposure target in >90% of 10,000 TB patients, we entered the popula-
tion pharmacokinetic parameter estimates of CAV and their inter-
individual variability in children and in adult TB patients, as well as
the lung penetration ratios (13, 38–40), in subroutinePRIORofADAPT
software (table S2). Each of the computational steps for the simulations
was outlined in detail in Materials andMethods. We validated the clin-
ical trial simulations using steps we previously described in detail (28).
Our simulations identified the ceftazidime and avibactam concen-
trations for the standard CAV dose of 50 mg/kg in 10,000 young chil-
dren (Fig. 7A), which was similar to those identified in the clinic with
that dose (38). This means that the simulation accurately achieved drug
concentrations achieved by specific doses in the children. For the expo-
sure target %TMIC of 47%, which gives similar microbial kill as themost
active standard first-line drugs, CAVdoses of 50, 100, 150, and 200mg/kg
infused over 2 hours every 8 hours achieved or exceeded the target at each
MIC in proportions of children shown in Fig. 7B. More than 90% of the
children treated with a CAV dose of 50 mg/kg achieved this exposure
target in Mtb isolates with an MIC of up to 32 mg/liter, 90% of those
treated with a CAV dose of 100 mg/kg achieved the target with an
MIC of up to 64 mg/liter, whereas 90% of the children treated with
CAV doses of 150 to 200mg/kg achieved or exceeded the target with an
MIC of up to 128 mg/liter. In the HFS-TB, a CAV %TMIC of 63% actu-
ally kills 11 timesmore than isoniazidmonotherapy,which could shorten
therapy duration. Figure 7C shows the target attainment for the%TMIC of
63% in children treatedwith the same four doses: TheMICs, abovewhich
target attainment falls to less than 90%,were one tube dilution lower than
the %TMIC of 47% target. Figure 7D is a summation over the entire MIC
range for the clinical isolates from South Africa and is the proportion of
10,000 childrenwho achieved each of the two exposure targets. Figure 7D
shows that the dose of 100 mg/kg, which has been shown to be tolerated
by children (40), would achieve exposures that kill as well as the first-line
anti-TB drugs in 90% of the children and would also achieve kill rates
faster than those for the first-line drugs in 60% of the children. Simula-
tions of 10,000 children patients for the avibactam component revealed
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Fig. 7. CAV dose target attainment in childhood TB. Each data point is shown as the proportion of 10,000 children. (A) Pharmacokinetic parameters and concen-
trations of ceftazidime and avibactam in 10,000 simulated children treated with a CAV dose of 50/12.5 mg/kg are compared to those observed in the clinic in children
treated with this same dose for other indications. Our simulated children achieved concentrations that are the same as those that were observed in the clinic by others
(used here to benchmark), meaning that the simulations faithfully recapitulated concentrations that are achieved in children by the different doses. (B) The dose of 100 mg/kg
achieved good target attainment for %TMIC of 47% up to an MIC of 64 mg/liter. (C) For the %TMIC of 63% target, only the dose of 200 mg/kg achieved good target attainment
up to an MIC of 64 mg/liter. (D) A summary of the proportion of 10,000 children with TB who achieved each of the two target %TMIC values of 47 and 63% over the entire MIC
range for each dose. The dose of 100 mg/kg achieves the target that gives the same kill rates as standard first-line drugs in 90% of the children and even higher kill rates in at
least 60% of the children. This means that the dose of 100 mg/kg is recommended for clinical testing in children with TB.
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that all tested doses achieved the target of 1 mg/liter of avibactam over
both 47 and 63% of dosing interval, when administered as the commer-
cially available CAV combination that has a ceftazidime/avibactam ratio
of 4:1.
We performed similar Monte Carlo experiments for adult cavitary
TB, in which 80% of Mtb is extracellular (16); patients have tolerated
seven to eight times the standard 2-g dose even as a continuous infusion
in the past (39, 40). Figure 8A shows that concentrations achieved in our
10,000 simulated adult patients were similar to those reported in the
FDAdocket in patients treated with a 2-g dose three times a day. There-
fore, our simulations accurately recapitulated concentrations achieved
by the specific doses in the clinic. Figure 8B shows that for exposure
target of %TMIC of 47%, the target attainment was achieved in >90%
of the patients with Mtb isolates that had CAV MICs of ≤16 mg/liter
for standard 2-g dose andMICs of up to 64mg/liter for 12-g dose a day.
Figure 8C shows that the more stringent exposure target of %TMIC of
63% was more difficult to achieve, at each MIC, in adults than in chil-
dren. Figure 8D shows the proportion of 10,000 adult TB patients who
would achieve each of the two exposure targets over the entire MIC
range; the graph flattens out after 12 g for the %TMIC of 47% target.
Therefore, 12 g is the dose to be used as salvage therapy in adult TB.
With regard to avibactam, all doses tested achieved the target of
1 mg/liter of avibactam over 47% of dosing interval. In summary, we
identified a CAV dose of 100 mg/kg in children, and 12-g dose a day
in adults would achieve kill rates similar to rifampin; 60% of children
actually exceed that kill rate.
DISCUSSION
We found that CAV has remarkable sterilizing effect at clinically achie-
vable concentrations. Neither ceftazidime nor avibactam on its own
killed Mtb, but the combined formulation did. This suggests that the
natural resistance of Mtb to ceftazidime is via degradation of the drug
and not because Mtb does not have the cephalosporin’s target. blaC is
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Fig. 8. CAV dose target attainment in adult-type TB. Each data point is shown as the proportion of 10,000 adult patients. (A) To validate that the simulations
reflected clinical reality, we compared the pharmacokinetic parameters of clearance and volume, as well as drug concentrations such as peak and AUC concentrations
achieved in the 10,000 simulated patients treated with the CAV dose of 2000/500 mg, to those observed in clinical pharmacokinetic studies published by others. It can be seen
that the values in the simulated subjects are almost exactly the same as those observed in actual patients by others, meaning that the simulations worked. (B) The proportion
of patients at each MIC who achieved a %TMIC of 47%, termed target attainment probability, in simulated subjects treated with doses between 2 and 16 g. As MIC increases,
the target attainment probability falls, but higher doses perform better until a dose of 12 g, above which there is no further improvement. (C) Target attainment probability for
the %TMIC target of 63% was poor for all doses examined in adults. (D) Proportion of 10,000 adult TB patients treated with different doses who achieved %TMIC of 47 or 63%
over the entire MIC range for each dose. The dose of 12 g achieves the target that gives the same kill rates as standard first-line drugs in 90% of the patients. This means that
the dose of 12 g is recommended for clinical testing in adults with TB.
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the lone gene that encodes a b-lactamase inMtb (41).Mtb BlaC shows
broad activity against cephalosporins such as ceftazidime; however, cla-
vulanate is a relatively poor inhibitor of this enzyme (42). In contrast,
avibactam is an effective BlaC inhibitor. However, none of our 12 resist-
ant isolates harbored aBlaCmutation. Instead, all 12CAV-resistant iso-
lates harbored both a PonA1 Prol631Ser and an RpfE Arg126Gln
nonconservative mutation. ponA1 encodes penicillin-binding protein
1 (PBP1), a bifunctional enzyme with a C-terminal transpeptidase in
residues 561 to 820, catalyzing (D,D) 4→3 linkages in peptidoglycan
synthesis and with a hydrolytic N-terminal domain transglycosylase
(43). Themutations in these genes inCAV-resistant isolates suggest that
PBP1 could be a putative site for CAV binding. CAV-resistant isolates
also had rpfA and rpfE mutations, encoding resuscitation protein
factors.Mtb’s five resuscitation protein factors share a lytic transglyco-
sylase domain and hydrolyze glycan chains in peptidoglycan. One of
these, rpfB, forms a complex with the endopeptidase RipA, which syn-
ergistically hydrolyses peptidoglycan; this hydrolysis action by the
complex is inhibited by PBP1 (43, 44). RipA also interacts with rpfE,
which shares 66% identity with rpfB (44). The rpf mutations further
suggest CAV interference with peptidoglycan synthesis. However, our
findings are not definitive and only give a plausible hypothesis of the
ceftazidime Mtb target; thus, more detailed biochemical work will be
needed to confirm our hypothesis.
In the global fight against TB, we have run out of options for the treat-
ment of many patients. Despite the recent introduction of bedaquiline
anddelamanid inhigh–TBburden countries, there continues to be a large
number of patients with incurable TB. We found that CAV, which is
already commercially available as a combined formulation, is likely to be
useful as salvage therapy for patients with difficult-to-treat TB: It can
also be added to bedaquiline and delamanid. Use of CAV circumvents
the need to use amoxicillin-clavulanate in conjunction with injectable
b-lactamsand the attendant commonside effects. In addition, the9-month
MDR-TB treatment regimen recently announced by the World Health
Organization includes aminoglycosides as an important part of the regi-
men. These injectables are associated with hearing loss of up to 70% in
some of adult patients and in up to 25% of children (45, 46). CAV could
be a less toxic alternative and arguably more effective. In addition,
CAV could be safer for use in neglected TB populations, such as preg-
nant women, for which anti-TB drugs with minimal teratogenicity are
needed. Finally, CAV has no known interactions with antiretroviral
agents and can thus be used in HIV/TB co-infection.
We identified aCAVdose of 100mg/kg three times aday for use in the
treatment of TB of children, and up to 12 g in adults, as optimal. Patients
have tolerated avibactam doses of up to 2000mg and ceftazidime doses of
up to 200 mg/kg as a continuous infusion in the past (38–40). However,
given that long-term administrationwould be required to treat TB, the full
side effect profile over longer treatment durations is unknown and will
require careful documentation. Nevertheless, given the urgent need, the
dose and dosing schedule should be tried as salvage therapy in patients
who have no other treatment options. We also identified a CAV suscep-
tibility breakpoint of 128mg/liter forMtb. This remains to be validated in
the future; however, the approach we used on HFS-TB findings followed
by Monte Carlo simulations has identified susceptibility breakpoints for
rifampin, isoniazid, andpyrazinamide,whichwere later confirmed in clin-
ical studies (34–37). This is also likely in the case of CAV.
Finally, we introduce a paradigm for rapid screening of different
antibiotics for effect against Mtb, examining susceptibility in X/MDR-TB
strains and thenquickly takingpromising candidates through steps to iden-
tify optimal doses. This approach takesmonths rather than years and could
alleviate the current crises while new anti-TB molecules are being devel-
oped. These medications, such as CAV, could be rapidly advanced to clin-
ical testing and to use as salvage therapy.
MATERIALS AND METHODS
Bacterial strains and cell lines
The following laboratory Mtb strains were used in the experiments:
H37Ra [American Type Culture Collection (ATCC) #25177], H37Rv
(ATCC#27294), CDC1551,HN878, andMtb 18b (donated by S. Cole).
The 25 clinical strains from TB patients were collected by the Medical
Research Council of South Africa. Human-derived THP-1 cells (ATCC
TIB-202), grown in RPMI 1640/10% FBS, were infected withH37Ra, as
described previously (19, 23, 29). All studies with virulent Mtb strains
were performed in a BSL3 laboratory.
Materials and drugs
Ceftazidime andCAVwere purchased from theBaylorUniversityMed-
ical Center pharmacy. Avibactam was purchased from BOC Sciences.
Hollow fiber cartridges were purchased from FiberCell.
Human and animal subjects
No human or animal studies or experiments were performed.
Determination of MICs
CAV (4:1 ratio) MICs were examined using the final ceftazidime con-
centrations of 0, 1, 2, 4, 8, 16, 32, 64, 128, and 256 mg/liter, in triplicate.
In theMGIT, the lowest concentration ofCAV that prevented the drug-
containing tube from fluorescing within 2 days of the drug-free tube or
control was defined as the MIC.
Hollow fiber system model of TB
In the HFS-TB experiments, 20 ml of Mtb cultures, preconditioned
either at pH 6.8 or 5.8 or in infected THP-1 cells, is inoculated into
peripheral compartments of HFS-TB preconditioned for 72 hours
(18, 19, 22). In the dose-effect study, CAV was administered at
ceftazidime-to-avibactam human equivalent doses of 0, 0.75 to 0.1875,
1.5 to 0.375, 3.0 to 0.75, 6.0 to 1.5, 12.0 to 3, 24.0 to 6, and 48.0 to 12 g for
27 days. Each drug infusion was over 2 hours. CAV concentration-
time profiles achieved in each HFS-TB were validated by sampling the
central compartment of each system at 0-, 1-, 4-, 7-, 9-, 12-, and 23-hour
time points. CAV drug concentration assays were described in “CAV
drug assay.” The peripheral compartments were sampled on days 0, 1, 2,
4, 7, 10, 14, 21, and 27 for quantification ofMtb. In the dose-fractionation
experiments, CAV was administered in one of three different dosing
schedules of (i) once per day, (ii) two times per day, and (iii) three times
per day for 10 days to achieve concentration-time profiles (Fig. 3, A to C).
We sampled the central compartment at 0, 2, 2.5, 3, 3.5, 5, 7.5, 10, 11.5, 14,
20, 22, and 23.5 hours over a 24-hour interval. The peripheral compart-
ments were sampled on days 0, 2, 4, 6, 8, and 10 for quantification ofMtb.
The subsequent HFS-TB studies examined a single CAV dosing
scheme, designed to achieve a %TMIC of 100% in an intracellular Mtb
HFS-TB model of H37Ra for 26 days and a sterilizing effect model of
Mtb H37Rv at pH 5.8. Central and peripheral compartments were
sampled for bacterial burden, as described above and in Results.
WGS of CAV-resistant isolates
DNA was extracted from CAV-resistant isolates using the methods de-
scribed previously (47). Sequencing libraries were prepared using KAPA
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Biosystem Hyper kit (KK8504). Six-bases-long unique barcodes were
added to each sample by ligating Illumina-compatible adapters and after
size selection libraries were amplified using four polymerase chain reac-
tion cycles, followed by cleaning using XP beads. About 9 pM of each
library was used for sequencing on HiSeq 2500 PE100 (paired-end 100
base pairs). After sequencing, all the reads were sorted on the basis of the
attached barcodes using SAM tools (http://samtools.sourceforge.net/).
Raw reads were processed to remove adapter artifacts and to deconvolute
the set of reads into their constituent isolates. Reads with no identifiable
barcode or with a barcode containing one or more ambiguous base calls
were excluded. CLCGenomicsWorkbench (v9.5.2) was used to perform
quality control (read quality, nucleotide content, and sequence
redundancy) as well as to align sequencing reads to the reference Mtb
genome NC_000962 and to make the variants call for SNV detection.
CAV drug assay
Ceftazidime concentrations in the samples collected from the central
compartment of HFS-TB were analyzed by liquid chromatography–
tandem mass spectrometry in positive ion mode. Ceftazidime and
ceftazidime-D5 (internal standard) were purchased from Toronto Re-
search Chemicals and Sigma, respectively. Calibrator, controls, and in-
ternal standard were included in each analytical run for quantitation.
Stock solutions of ceftazidime and internal standard were prepared in
80:20methanol/water at a concentrationof 1mg/ml and stored at−20°C.
A seven-point calibration curve was prepared by diluting ceftazidime
stock solution in drug-free media (0.25, 1, 5, 10, 25, 50, and 100 mg/ml).
Quality control samples were prepared by spiking media with stock
standards for two levels of controls of 0.4 and 8 mg/ml. Samples were
prepared in 96-well microliter plates by adding 10 ml of calibrator, qual-
ity controls, or sample to 190 ml of 0.1% formic acid in water containing
internal standard (1 mg/ml) followed by vortex. Chromatographic sep-
aration was achieved on an Acquity UPLC HSS T3 analytical column
(1.8 mm, 50 × 2.1 mm) (Waters) maintained at 30°C at a flow rate of
0.2 ml/min with a binary gradient with a total run time of 6 min. The
observed ion mass/charge ratio (m/z) values of the fragment ions were
547.11→468.11 for ceftazidime and 552.15→468.11 ceftazidime-D5.
Sample injection and separation were performed using Acquity UPLC
interfaced with a Xevo TQ mass spectrometer (Waters). All data were
collected usingMassLynx version 4.1 SCN810. The limit of quantitation
for this assaywas 0.25 mg/ml. The between-day andwithin-day percent-
age coefficients of variation were 14 and 21%, respectively.
Pharmacokinetic and pharmacodynamic modeling
Ceftazidime, avibactam, rifampin, pyrazinamide, and isoniazid concen-
trations were analyzed using ADAPT software, as described previously
(29). Pharmacokinetic parameter estimates identified in themodels were
then used to calculate the AUC0–24, AUC0–24/MIC, peak/MIC, and %
TMIC in eachHFS-TB. Formonotherapy experiments, microbial kill ver-
sus exposure was examined using the inhibitory sigmoid Emax model.
Monte Carlo experiments
Monte Carlo experiments allow for examination of different drug doses
to determine whether they will achieve the exposure targets associated
with specific rates of microbial kill in patients. We examined this target
attainment in at least 10,000 patients; this number is required to stabilize
the tail of the variance. Population pharmacokinetic parameter esti-
mates for CAV, and their covariance, for either children or adults
that are shown in table S2 were based on studies published previously
(13, 38–40), were entered as domain of input into subroutine PRIOR
of ADAPT software. Both normal and lognormal distributions were
examined.We used the option for population simulationwithout noise.
The following doses were examined for children with TB: 50, 100, 150,
and 200mg/kg. The following doses were examined for adults with TB:
2, 4, 6, 8, 12, 14, and 16 g. We used two levels of validation. For the first
level, we compared the simulated data to determine whether the phar-
macokinetic parameter estimates and variances in the simulated
subjects were similar to the data sets entered into the domain of input.
For the second level of validation, we examined a separate database,
such as the one reported to the FDA, to determine whether the drug
concentrations achieved by the standard doses were similar to those
we identified in our Monte Carlo experiments.
Each of the doses was examined for the ability to achieve, or exceed,
the target CAV exposure%TMIC of either 47 or 63%derived in theHFS-
TB studies, at each MIC. We examined each of these for MICs ranging
from 2 to 128mg/liter, based on a twofold dilution. TheMIC range was
from our results in Fig. 2H. Probability of target attainment (PTA) at
each MIC was used to calculate the cumulative proportion of patients
[also termed cumulative fractional response (CFR)] who would achieve
or exceed the target ceftazidime exposure target %TMIC of either 47 or
63%, on summation over the MIC range based on the formula
CFR ¼∑ni¼1PTAi*Fi
where PTA is at each MIC and F is the proportion of isolates at each
MIC (i). For avibactam, the target concentration was 1 mg/liter. The
percentage of time that avibactam concentration persisted above
1 mg/liter was set to be equal to the %TMIC for ceftazidime (47 or
63%), assuming that ceftazidime only works when sufficient concentra-
tions of avibactam are achieved. We assumed a ceftazidime/avibactam
concentration ratio of 4:1 in all simulations, as in the current commer-
cial preparation.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/8/e1701102/DC1
fig. S1. Relationship between %TMIC and TTP.
table S1. List of mutations in 12 CAV-resistant Mtb strains.
table S2. Pharmacokinetic parameter input into PRIOR versus parameters achieved in 10,000
simulated patients.
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